肠道微生物群和新的微生物群向药物治疗困难菌感染
Ahran Lee1, Jung Sik Yoo1, Eun-Jeong Yoon1
1Division of Antimicrobial Resistance Research, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Republic of Korea.
Antibiotics (Basel, Switzerland)
|October 25, 2024
概括
困难菌感染 (CDI) 与肠道微生物组的变化有关. 治疗重点是恢复肠道微生物群,包括一种新的FDA批准的药物.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 困难菌是抗生素相关腹的主要原因.
- 困难菌感染 (CDI) 的危险因素包括抗生素使用,PPI,年龄和住院治疗,往往导致肠道疾病.
- CDI可能导致严重的,危及生命的疾病.
研究的目的:
- 审查与CDI相关的流行病学和肠道微生物组特征.
- 引入针对CDI的微生物组向治疗方法.
- 为了突出最近FDA批准的基于微生物组的疗法.
主要方法:
- 关于CDI流行病学的文献综述.
- 在CDI中分析肠道微生物组和代谢物变化.
- 微生物组调节治疗策略的概述.
主要成果:
- 肠道失调和改变的代谢物是CDI发展的关键因素.
- 恢复肠道微生物组的组成是CDI的治疗目标.
- 一种针对微生物组的新药获得了美国FDA的批准.
结论:
- 了解CDI相关的肠道微生物组变化对于治疗至关重要.
- 基于微生物组的疗法代表了管理CDI的有希望的新方法.
- 最近的FDA批准意味着向微生物向干预措施的转变.
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
109
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
109
Drugs for Treatment of Diarrhea-Predominant IBS
149
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
149
Bacterial Flora of the Large Intestine
392
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
392
Drugs for Treatment of Constipation-Predominant IBS
139
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
139
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124


